-+ 0.00%
-+ 0.00%
-+ 0.00%

Aura Biosciences Q3 net loss widens 23% to $32.07 million

PUBT·11/09/2026 12:09:30
Listen to the news
Aura Biosciences Q3 net loss widens 23% to $32.07 million
  • Aura Biosciences’ third-quarter 2026 net loss widened 23% year-over-year to $32.07 million.
  • General and administrative expenses jumped 80% to $10.32 million, primarily due to restructuring charges.
  • Cash, cash equivalents and marketable securities totaled $297.2 million at September 30, 2026, with funding expected into first-half 2029.
  • Phase 3 CoMpass topline data remain on track for second-half 2027; all participants have completed treatment visits.
  • A new CDMO relationship will establish designated manufacturing capacity for bel-sar development and commercial supply.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872571) on November 09, 2026, and is solely responsible for the information contained therein.